Artificial intelligence (AI) is certainly in the news constantly; however, it’s been used in drug discovery for some time.A new collaboration between artificial intelligence drug discovery company Insilico Medicine and University of Toronto biochemist and molecular geneticist Igor Stagljar will test AI-designed molecules against "undruggable" cancer targets. The research will test 15 to 20 undruggable targets - but are they undruggable? And how does AI work in the drug discovery process?This week, we have a conversation with Kyle Tretina, Alliance Manager of AI Platforms at Insilico Medicine, on a wide range of subjects including drug discovery, undruggable targets, the collaboration with the University of Toronto, and more.00:58-05:11: About Insilico Medicine05:11-06:09: Why is AI in the news?06:09-07:39: Helping people through AI07:39-09:10: What is Insilico Medicine doing with AI?09:10-10:15: Does Insilico Medicine take drugs from idea to trials?10:15-11:32: How do your partnerships come about?11:32-19:34: How does drug development start with AI?19:34-24:43: Can AI address undruggable targets?24:43-25:05: What do you need to do after finding a potential drug?25:05-27:57: Can quantum computing aid drug development?27:57-30:13: How can AI help reduce costs and save time?30:13-32:56: What is your partnership with the University of Toronto?32:56-36:24: What is the timescale for introducing drugs from AI?36:24-37:29: What conditions are you working on?Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter